-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Gout and high uric acidemia has gradually become a kind of serious metabolic diseases, the incidence rate is increasing year by year, and closely related to a series of complications, the current first-line drug has poor efficacy, side effects and other defects, at the same time in patients have certain restrictions on use.
as the first URAT1 inhibitor drug to be marketed, Lesinurad showed only moderate ller effects and more clinical toxic side effects in several Phase III clinical trials.
WXSH0493 is based on the problems exposed by lesinurad in clinical applications, focusing on how to improve drug ability, how to reduce OAT4 inhibition, how to avoid highly active metabolic intermediates and other key issues, and achieved positive results.
WXSH0493 will provide a new drug option in the clinical treatment of patients with geryro and hypoureticemia, which is expected to address the unsolved clinical needs of these patients and has significant clinical value.
the date of disclosure of this announcement, the Company has invested 22.5858 million yuan in research and development of WXSH0493 tablets.
WXSH0493 is a highly active, high-safety URAT1 inhibitor, clinically positioned to improve the effectiveness and safety of lesinurad in clinical use, so its market positioning is a first-line drug for gyro and high uric acidemia.
currently, clinical first-line medications for high uric acidemia and gout mainly include paracetamol, non-clothing, propylene sulfonshu, benzo bromine malone, akidolic and lesinurad.
, according to the Miner database data show that the current domestic sales of similar drugs accounted for a higher proportion of non-brocade, benzo bromomalon, benzoyl alcohol.
sales of public, urban communities, county-level public and township health hospitals in China in 2019 amounted to about 1.512 billion yuan, an increase of 39.13% over the previous year; Total sales of health hospitals amounted to about 400 million yuan, an increase of 5.45 percent over the previous year, while sales of allopurol in China's urban public, urban communities, county-level public and township health hospitals in 2019 amounted to about 118 million yuan, down 22.95 percent from the previous year.
.